Pacira Pharmaceuticals Sets New 12-Month High at $106.57 (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) reached a new 52-week high during trading on Monday , AR Network reports. The stock traded as high as $106.57 and last traded at $106.57, with a volume of 126,414 shares. The stock had previously closed at $104.73.
A number of analysts have recently weighed in on PCRX shares. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $98.00 to $110.00 in a research note on Friday, August 1st. Separately, analysts at Canaccord Genuity raised their price target on shares of Pacira Pharmaceuticals to $114.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 1st. They now have a $109.00 price target on the stock, up previously from $86.00. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $104.68.
The stock has a 50-day moving average of $93.2 and a 200-day moving average of $79.29. The company’s market cap is $3.859 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, July 31st. The company reported $0.04 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.25. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $42.20 million. Pacira Pharmaceuticals’s revenue was up 175.2% compared to the same quarter last year. Analysts expect that Pacira Pharmaceuticals will post $0.23 EPS for the current fiscal year.
In other Pacira Pharmaceuticals news, Director Andreas Wicki unloaded 150,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $101.25, for a total value of $15,187,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.